Prescrire IN ENGLISH - HOME

Register online | Log in | My Prescrire

Issue contents

About Prescrire

english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent : 1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Spotlight

100 most recent
Archives

The WHO urges governments to stand up to health-harming corporations

Editorial In 2024, the World Health Organization (WHO) published a new landmark document that is both a review of the scientific literature and a political analysis, in the broad sense of the term, this time on the health-harming effects of the products and practices of certain sectors of industry (1-5).
Full article available for download (free)

1 January 2025

RSVPreF3/AS01E vaccine (Arexvy°) in the prevention of RSV infections from 60 years of age

Marketing Authorisations The adjuvanted RSVPreF3/AS01E vaccine is the first vaccine authorised in the European Union for the prevention of RSV-associated lower respiratory tract infections in adults aged 60 years or older. Does it prevent respiratory infections in this population? Does it reduce hospitalisations and mortality? And what are its adverse effects?
Full article available for download by subscribers (4 pages)

1 January 2025

Valoctocogene roxaparvovec (Roctavian°) in haemophilia A?

Marketing Authorisations The gene therapy product valoctocogene roxaparvovec consists of a non-replicating adeno-associated virus serotype 5 (AAV5)-based vector that contains a DNA sequence encoding a variant of human factor VIII. It has been authorised in the European Union for the treatment of adults with severe haemophilia A on the basis of weak non-comparative data that suggest efficacy, but which declines over time.
Full article available for download by subscribers

1 January 2025

Neuroleptics in patients with dementia: serious adverse effects

Adverse Effects In 2024, a study using a British general practice database, linked to hospitalisation and mortality data, investigated several known adverse effects of neuroleptics in patients with dementia who were aged 50 years or older.
Full article available for download by subscribers

1 January 2025

Dupilumab in severe asthma in children: helpful and without risk of infections or cancer?

Queries and Comments Following the publication of Prescrire's analysis of evaluation data for dupilumab (Dupixent°) in severe asthma in children aged 6 years or older (Prescrire Int October 2023), members of Crisalis, an international clinical research network studying severe asthma, wrote to express their differing conclusions on dupilumab's benefits and harms in this situation.
Full article available for download by subscribers (3 pages)

1 January 2025

Revision of European pharmaceutical legislation: an opportunity to transform the system of R&D incentives

Outlook In the context of the ongoing revision of European pharmaceutical legislation, a report by the European Parliament's Panel for the Future of Science and Technology has set out options for major changes to Europe's pharmaceutical research and development (STOA) system. Here, Prescrire publishes excerpts from the report's insightful analyses providing clarifications in the form of editors' notes.
Full article (4 pages) available for download (free)

1 January 2025

Too many scientific articles continue to be cited after their retraction

Outlook About 60 out of 100 000 articles are retracted after publication. Unfortunately, those who read or cite them are not always aware of their retracted status.
Full article available for download (free)

1 January 2025

Paradigm(s)

Editorial For decades, the pharmaceutical industry has encouraged patients, students, healthcare professionals and drug regulatory agencies to adopt a way of thinking about drugs focused on their efficacy, trivialising the issue of adverse effects and sometimes even obscuring the dangers they pose to patients.
Full article available for download (free)

1 December 2024

Ivosidenib (Tibsovo°) in the first-line treatment of acute myeloid leukaemia with an IDH1 mutation

Marketing Authorisations Ivosidenib has been authorised in the European Union, in combination with azacitidine, for the first-line treatment of adult patients with acute myeloid leukaemia and an IDH1 mutation, for whom high-dose cytotoxic chemotherapy is unsuitable. Due to their concurrent development, the azacitidine + ivosidenib combination has not been compared to the azacitidine + venetoclax combination.
Full article available for download by subscribers (4 pages)

1 December 2024

Levetiracetam in utero: long-term effects more clearly defined

Adverse effects Levetiracetam is an antiepileptic drug for which no particular safety signal has been reported following exposure as monotherapy during the first trimester of pregnancy. As of mid-2024, what is known about the consequences of in-utero exposure to levetiracetam in terms of neuropsychiatric developmental disorders?
Full article available for download by subscribers

1 December 2024

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90